NCT00919607View on ClinicalTrials.gov

Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Schizophrenia
Interventions
DRUG

quetiapine fumarate extended-release

200mg,oral,single dose

DRUG

quetiapine fumarate extended-release

300mg,oral,single dose

Trial Locations (1)

Unknown

Research Site, Beijing

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY